Advertisement
Australia markets closed

  • ALL ORDS

    7,974.80
    -27.70 (-0.35%)
     

  • ASX 200

    7,724.30
    -25.40 (-0.33%)
     

  • AUD/USD

    0.6618
    -0.0020 (-0.30%)
     

  • OIL

    78.49
    -0.13 (-0.17%)
     

  • GOLD

    2,348.40
    +30.40 (+1.31%)
     

  • Bitcoin AUD

    100,034.90
    +1,107.20 (+1.12%)
     

  • CMC Crypto 200

    1,404.53
    -13.34 (-0.94%)
     

  • AUD/EUR

    0.6178
    +0.0005 (+0.09%)
     

  • AUD/NZD

    1.0765
    +0.0012 (+0.12%)
     

  • NZX 50

    11,864.89
    -7.75 (-0.07%)
     

  • NASDAQ

    19,659.80
    +82.88 (+0.42%)
     

  • FTSE

    8,146.86
    -16.81 (-0.21%)
     

  • Dow Jones

    38,589.16
    -57.94 (-0.15%)
     

  • DAX

    18,002.02
    -263.66 (-1.44%)
     

  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     

  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference

Business Wire
·1-min read

CONCORD, Calif., May 22, 2024--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 21st Annual Craig-Hallum Institution Investor Conference in Minneapolis, on Wednesday, May 29th.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

ADVERTISEMENT

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522601002/en/

Contacts

Jessica Hanover – Vice President, Corporate Affairs
Cerus Corporation
925-288-6137